Terns Pharmaceuticals Inc. Updates
Date of Release: 2026‑01‑02Exchange: Nasdaq (Ticker: TERN)Market Capitalisation: USD 4.39 billionClosing Price (2026‑01‑01): USD 40.1152‑Week High: USD 48.26 (2025‑12‑09)52‑Week Low: USD 1.865 (2025‑04‑06)Price‑to‑Earnings Ratio: –38.81
1. Inducement Grants to New Employees
On 11 December 2025, Terns Pharmaceuticals announced that it had closed its inducement grant program for newly hired employees in compliance with Nasdaq Listing Rule 5635(C)(4). The program, aimed at retaining key personnel, granted stock awards that vest over a multi‑year period. The company stated that the grants were consistent with its strategy to attract and retain talent critical to the development of its oral and molecular‑targeted therapies for liver disease and cancer.
2. Share Price Surge on CML Treatment Potential
The same day, the company reported that its shares had risen by 630 % on the market, reflecting investor enthusiasm for a best‑in‑class chronic myeloid leukaemia (CML) treatment that is currently in late‑stage clinical development. The dramatic price appreciation was noted by financial media outlets, including InsiderMonkey, which highlighted the company’s rapid growth trajectory and the potential upside of its pipeline.
3. Contextualising the Performance
The recent surge in share price coincides with the company’s broader strategy of pursuing oral, molecular‑targeted drugs for oncology indications. While the 52‑week range shows a high of USD 48.26 and a low of USD 1.865, the current valuation at USD 40.11 indicates a strong upward trend. The negative price‑to‑earnings ratio underscores that the company is still in a developmental phase, with earnings expected to materialise only upon successful regulatory approval and commercial launch of its product candidates.
4. Outlook
Terns Pharmaceuticals remains a Nasdaq‑listed biopharmaceutical firm headquartered in Foster City, California, with a global customer base. The company’s focus on liver disease and cancer, coupled with its recent employee inducement grants and significant share price appreciation, positions it as a notable player in the oncology sector. Investors and analysts should monitor upcoming clinical trial milestones and regulatory submissions for further insights into the company’s trajectory.
